Should I buy or sell Alphatec stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATEC shares. View ATEC analyst ratings or view top-rated stocks .

What is Alphatec's stock price target for 2024?

7 analysts have issued 12-month price objectives for Alphatec's shares. Their ATEC share price targets range from $16.00 to $32.00. On average, they expect the company's stock price to reach $21.86 in the next year. This suggests a possible upside of 86.7% from the stock's current price. View analysts price targets for ATEC or view top-rated stocks among Wall Street analysts .

How have ATEC shares performed in 2023?

Alphatec's stock was trading at $12.35 at the start of the year. Since then, ATEC shares have decreased by 5.2% and is now trading at $11.71. View the best growth stocks for 2023 here .

When is Alphatec's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our ATEC earnings forecast .

How were Alphatec's earnings last quarter?

Alphatec Holdings, Inc. (NASDAQ:ATEC) released its quarterly earnings results on Monday, November, 6th. The medical technology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.05. The medical technology company earned $118.26 million during the quarter, compared to analyst estimates of $115.30 million.

What ETFs hold Alphatec's stock?

ETFs with the largest weight of Alphatec (NASDAQ:ATEC) stock in their portfolio include Jacob Forward ETF (JFWD) , Innovator IBD 50 ETF (FFTY) , SPDR S&P Health Care Equipment ETF (XHE) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH) . First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) .

What guidance has Alphatec issued on next quarter's earnings?

Alphatec issued an update on its third quarter 2023 earnings guidance on Monday, October, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $117.70 million-$118.50 million, compared to the consensus revenue estimate of $111.78 million.

What is Pat Miles' approval rating as Alphatec's CEO?

19 employees have rated Alphatec Chief Executive Officer Pat Miles on Glassdoor.com . Pat Miles has an approval rating of 72% among the company's employees. 63.0% of employees surveyed would recommend working at Alphatec to a friend.

What other stocks do shareholders of Alphatec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alphatec investors own include Macrocure Ltd. - Ordinary Share (MCUR) , LinnCo (LNCOQ) , California Resources (CRC) , Sorrento Therapeutics (SRNE) , Catalyst Pharmaceuticals (CPRX) , (GBSN) (GBSN) , Idera Pharmaceuticals (IDRA) , Athersys (ATHX) , Anavex Life Sciences (AVXL) and BioCryst Pharmaceuticals (BCRX) .

Who are Alphatec's major shareholders?

Alphatec's stock is owned by many different retail and institutional investors. Top institutional investors include Fred Alger Management LLC (1.71%), Assenagon Asset Management S.A. (1.32%), Royal Bank of Canada (1.14%), abrdn plc (1.15%), New York State Common Retirement Fund (0.73%) and Walleye Capital LLC (0.58%). Insiders that own company stock include Craig E Hunsaker , David H Mowry , David M Demski, David R Pelizzon , David Sponsel , Elizabeth Ann Altman, Evan Bakst , James L L Tullis, James L L Tullis , Jason Hochberg , Jeffrey G Black , Jennifer N Pritzker, Jennifer N Pritzker , John Todd Koning, L-5 Healthcare Partners, Llc, Mortimer Berkowitz III, Patrick Miles , Paul Segal and Scott Lish . View institutional ownership trends .

How do I buy shares of Alphatec?

Shares of ATEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Alphatec Stock Price, News & Analysis (NASDAQ:ATEC)

$11.71

-0.24 (-2.01%)

(As of 11/28/2023 ET)

Compare

Today's Range: $11.46
▼
$11.97
50-Day Range: $8.89
▼
$13.18
52-Week Range: $8.66
▼
$19.14

Volume: 1.40 million shs
Average Volume: 1.35 million shs
Market Capitalization: $1.60 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.86

Alphatec MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 86.7% Upside
$21.86 Price Target
Short Interest: Bearish
8.61% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.67
Upright™ Environmental Score
News Sentiment: 0.63
Based on 2 Articles This Week
Insider Trading: Selling Shares
$3.27 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.44) to ($1.00) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

332nd out of 949 stocks

Surgical & Medical Instruments Industry

44th out of 95 stocks

3.5

Analyst's Opinion

Consensus Rating
Alphatec has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.86, Alphatec has a forecasted upside of 86.7% from its current price of $11.71.
Amount of Analyst Coverage
Alphatec has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.61% of the outstanding shares of Alphatec have been sold short.
Short Interest Ratio / Days to Cover
Alphatec has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in Alphatec has recently increased by 1.29%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Alphatec does not currently pay a dividend.
Dividend Growth
Alphatec does not have a long track record of dividend growth.

3.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Alphatec has received a 37.18% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cervical implants", "Medical screws", and "Lumbar spinal stenosis treatment instruments" products. See details.
Environmental Sustainability
The Environmental Impact score for Alphatec is -1.67.

1.5

News and Social Media Coverage

News Sentiment
Alphatec has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Alphatec this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for ATEC on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Alphatec to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alphatec insiders have sold 937.98% more of their company's stock than they have bought. Specifically, they have bought $315,000.00 in company stock and sold $3,269,645.00 in company stock.
Percentage Held by Insiders
29.12% of the stock of Alphatec is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
67.19% of the stock of Alphatec is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Alphatec are expected to grow in the coming year, from ($1.44) to ($1.00) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alphatec is -7.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alphatec is -7.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Alphatec Stock (NASDAQ:ATEC)

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. It manufactures and sells implants and instruments through third-party suppliers. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform; Sigma PTP Access and Patient Positioning System; split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; EOS imaging system that provides full-body imaging; spinal implants and fixation systems; and NanoTec and Calibrate PSX, as well as various standalone implants for height restoration and stabilization. It also provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix, a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM; AlphaGRAFT Demineralized Bone Matrix comprising demineralized human tissues; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives in the United States and internationally. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

ATEC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATEC Stock News Headlines

November 28, 2023 | americanbankingnews.com

Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $21.86 Consensus Target Price from Brokerages

November 12, 2023 | finance.yahoo.com

With 54% ownership of the shares, Alphatec Holdings, Inc. (NASDAQ:ATEC) is heavily dominated by institutional owners

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 9, 2023 | seekingalpha.com

Alphatec: Still Not Having My Back

November 7, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), Madrigal Pharmaceuticals (MDGL) and Alphatec Holdings (ATEC)

November 7, 2023 | ca.sports.yahoo.com

Q3 2023 Alphatec Holdings Inc Earnings Call

November 7, 2023 | finance.yahoo.com

Alphatec Holdings, Inc. (NASDAQ:ATEC) Q3 2023 Earnings Call Transcript

November 6, 2023 | seekingalpha.com

Alphatec Holdings, Inc. 2023 Q3 - Results - Earnings Call Presentation

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 6, 2023 | msn.com

Alphatec GAAP EPS of -$0.35

November 6, 2023 | finance.yahoo.com

ATEC Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Adjusted EBITDA Guidance

November 6, 2023 | finance.yahoo.com

Alphatec Holdings Inc (ATEC) Reports 32% Revenue Growth in Q3 2023, Raises Full Year EBITDA Guidance

November 5, 2023 | finance.yahoo.com

ATEC Nov 2023 10.000 call

November 3, 2023 | msn.com

Alphatec Q3 2023 Earnings Preview

October 31, 2023 | finance.yahoo.com

ATEC Equipped to Support Ramping Surgical Volume With Proceeds From Secondary Offering

October 27, 2023 | finance.yahoo.com

ATEC Announces Closing of Public Stock Offering

October 26, 2023 | marketwatch.com

Alphatec Holdings Shares Fall Premarket After Offering Priced

October 26, 2023 | msn.com

Alphatec drops 15%, prices $150M stock offering at $10.50 per share

October 26, 2023 | markets.businessinsider.com

Why Alphatec Holdings Inc (ATEC) Stock Is Falling

October 25, 2023 | finance.yahoo.com

Why Alphatec Holdings Stock Plunged Today

October 25, 2023 | benzinga.com

Why Alphatec (ATEC) Stock Is Nosediving

October 24, 2023 | msn.com

Alphatec commences proposed public offering

October 24, 2023 | marketwatch.com

Alphatec Shares Fall 14% as Co. Commences $150M Public Offering

October 24, 2023 | finance.yahoo.com

Alphatec Holdings, Inc. (L1Z1.F)

October 20, 2023 | msn.com

Roth MKM Initiates Coverage of Alphatec Holdings (ATEC) with Buy Recommendation

October 20, 2023 | markets.businessinsider.com

What 6 Analyst Ratings Have To Say About Alphatec Holdings

October 17, 2023 | finance.yahoo.com

ATEC Enhances Board with Renowned Spine Prowess

See More Headlines

Receive ATEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alphatec and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:ATEC
CUSIP: 02081G10
CIK: 1350653
Web: www.atecspine.com
Phone: (760) 431-9286
Fax: 800-922-1356
Employees: 705
Year Founded: 1990

Price Target and Rating

Average Stock Price Target: $21.86
High Stock Price Target: $32.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +86.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-152,150,000.00
Net Margins: -38.32%
Pretax Margin: -38.43%
Return on Equity: N/A
Return on Assets: -28.98%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.25
Quick Ratio: 1.37

Sales & Book Value

Annual Sales: $350.87 million
Price / Sales: 4.55
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.35) per share
Price / Book: -33.46

Miscellaneous

Outstanding Shares: 136,300,000
Free Float: 96,610,000
Market Cap: $1.60 billion
Optionable: Not Optionable
Beta: 1.35

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Patrick S. Miles (Age 57)
Executive Chairman, CEO & President
Comp: $1.59M
Mr. J. Todd Koning (Age 50)
Executive VP & CFO
Comp: $815.29k
Mr. David P. Sponsel (Age 44)
Executive Vice President of Sales
Comp: $848.19k
Mr. Craig E. Hunsaker (Age 59)
Executive VP of People and Culture
Comp: $909.33k
Mr. Eric Dasso (Age 50)
Executive Vice President of Adjunctive Technologies
Comp: $1M
Mr. Tyson Eliot Marshall (Age 49)
General Counsel & Corporate Secretary
Mr. Ali Shorooghi (Age 37)
Senior Vice President of Marketing
Mr. Jonathan Allen (Age 63)
Executive Vice President of Commercial Operations
Mr. Scott Lish (Age 42)
Senior Vice President of Research & Development
Dr. Luiz Pimenta
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATEC Stock Analysis - Frequently Asked Questions

Should I buy or sell Alphatec stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATEC shares.
View ATEC analyst ratings or view top-rated stocks.
What is Alphatec's stock price target for 2024?: 7 analysts have issued 12-month price objectives for Alphatec's shares. Their ATEC share price targets range from $16.00 to $32.00. On average, they expect the company's stock price to reach $21.86 in the next year. This suggests a possible upside of 86.7% from the stock's current price.
View analysts price targets for ATEC or view top-rated stocks among Wall Street analysts.
How have ATEC shares performed in 2023?: Alphatec's stock was trading at $12.35 at the start of the year. Since then, ATEC shares have decreased by 5.2% and is now trading at $11.71.
View the best growth stocks for 2023 here.
When is Alphatec's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ATEC earnings forecast.
How were Alphatec's earnings last quarter?: Alphatec Holdings, Inc. (NASDAQ:ATEC) released its quarterly earnings results on Monday, November, 6th. The medical technology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.05. The medical technology company earned $118.26 million during the quarter, compared to analyst estimates of $115.30 million.
What ETFs hold Alphatec's stock?: ETFs with the largest weight of Alphatec (NASDAQ:ATEC) stock in their portfolio include Jacob Forward ETF (JFWD), Innovator IBD 50 ETF (FFTY), SPDR S&P Health Care Equipment ETF (XHE) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

What guidance has Alphatec issued on next quarter's earnings?: Alphatec issued an update on its third quarter 2023 earnings guidance on Monday, October, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $117.70 million-$118.50 million, compared to the consensus revenue estimate of $111.78 million.
What is Pat Miles' approval rating as Alphatec's CEO?: 19 employees have rated Alphatec Chief Executive Officer Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among the company's employees. 63.0% of employees surveyed would recommend working at Alphatec to a friend.
What other stocks do shareholders of Alphatec own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alphatec investors own include Macrocure Ltd. - Ordinary Share (MCUR), LinnCo (LNCOQ), California Resources (CRC), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), (GBSN) (GBSN), Idera Pharmaceuticals (IDRA), Athersys (ATHX), Anavex Life Sciences (AVXL) and BioCryst Pharmaceuticals (BCRX).
Who are Alphatec's major shareholders?: Alphatec's stock is owned by many different retail and institutional investors. Top institutional investors include Fred Alger Management LLC (1.71%), Assenagon Asset Management S.A. (1.32%), Royal Bank of Canada (1.14%), abrdn plc (1.15%), New York State Common Retirement Fund (0.73%) and Walleye Capital LLC (0.58%). Insiders that own company stock include Craig E Hunsaker, David H Mowry, David M Demski, David R Pelizzon, David Sponsel, Elizabeth Ann Altman, Evan Bakst, James L L Tullis, James L L Tullis, Jason Hochberg, Jeffrey G Black, Jennifer N Pritzker, Jennifer N Pritzker, John Todd Koning, L-5 Healthcare Partners, Llc, Mortimer Berkowitz III, Patrick Miles, Paul Segal and Scott Lish.
View institutional ownership trends.
How do I buy shares of Alphatec?: Shares of ATEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ATEC) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial